Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,174 across all filing types
Latest filing 2024-07-23 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2024 ,inter alia, to consider and approve the unaudited financial results of the ....
Regulatory Filings Classification · 95% confidence The document is a notice from Lupin Limited addressed to stock exchanges about an upcoming Board of Directors meeting scheduled for August 6, 2024. The purpose of the meeting includes considering and taking on record the unaudited financial results for the quarter ended June 30, 2024. The document is short (1587 characters) and serves as an announcement of a future event rather than containing any financial data or results itself. It does not contain actual financial statements or detailed analysis, nor is it a transcript or report. It is a regulatory announcement informing the market about the board meeting and the upcoming financial results release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2024-07-23 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings Classification · 95% confidence The document is a short notice dated July 23, 2024, addressed to stock exchanges, informing about a forthcoming Board of Directors meeting scheduled for August 6, 2024. The purpose of the meeting is to consider and take on record the unaudited financial results for the quarter ended June 30, 2024. The document does not contain any financial data or results itself, but merely announces the upcoming meeting and the agenda. It is also quite brief (1577 characters). According to the 'Menu vs Meal' rule, such a short announcement about an upcoming report or meeting is classified as a Regulatory Filing (RNS) rather than an Interim Report (IR) or Earnings Release (ER). Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-07-23 English
Intimation regarding loss of share certificate by the shareholder.
Regulatory Filings Classification · 100% confidence The document is a compliance certificate submitted under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificate(s) for a shareholder and is addressed to stock exchanges. The document is short (2874 characters) and serves as a regulatory compliance filing rather than a financial report or announcement of voting results. It does not contain financial data, management changes, or meeting materials. It is primarily a regulatory compliance certificate related to share certificate loss reporting. Therefore, it fits best under Regulatory Filings (RNS) as a compliance certificate filing.
2024-07-17 English
Loss of Share Certificates
Regulatory Filings Classification · 100% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, regarding the loss of share certificate details received from a shareholder. It is addressed to stock exchanges and signed by the company secretary. The document is short (2874 characters) and does not contain financial statements or performance data. It is a regulatory compliance communication related to share certificate loss, not a financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-17 English
Reply to Clarification Sought
Board/Management Information Classification · 100% confidence The document is a letter addressed to the National Stock Exchange of India Limited, disclosing the appointment of an Independent Director, Mr. Alfonso Zulueta, effective May 6, 2024. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about changes in the company's board or management. The content is focused on announcing a board appointment and confirming the director is not debarred by regulatory authorities. There is no financial data, report, or other types of filings such as earnings, audit, or annual reports. The document fits the category of Board/Management Information (MANG) as it announces a change in senior management/board of directors.
2024-07-15 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release dated July 15, 2024, announcing the divestiture of Lupin Limited's U.S. Commercial Women’s Health Specialty Business to Evofem Biosciences. It includes details about the transaction, the companies involved, and forward-looking statements. There are no financial statements, detailed financial performance data, or regulatory form filings such as 10-K or 10-Q. The document is a corporate announcement about a business divestiture, which fits the category of Capital/Financing Update (CAP) as it relates to a significant transaction affecting the company's business and capital structure. The document length (9065 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive update on a financing-related transaction.
2024-07-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.